Back to today’s briefing

Story perspectives

FDA Approves Wegovy HD for Weight Loss, Safety Concerns Remain

3/25/2026

50 8 Full Breakdown

Summary

Story summary

On March 19, 2026, the U.S. Food and Drug Administration approved Wegovy HD (semaglutide 7.2 mg) to aid weight loss and maintenance in adults with obesity.
Clinical trials show an average weight loss of 20.7% with the higher dose.
The approval reflects an FDA push to expedite health solutions and strengthens Novo Nordisk's obesity drug position.
Safety concerns include gastrointestinal side effects and contraindications for certain patients.

1 of 1

Story summary

On March 19, 2026, the U.S. Food and Drug Administration approved Wegovy HD (semaglutide 7.2 mg) to aid weight loss and maintenance in adults with obesity.
Clinical trials show an average weight loss of 20.7% with the higher dose.
The approval reflects an FDA push to expedite health solutions and strengthens Novo Nordisk's obesity drug position.
Safety concerns include gastrointestinal side effects and contraindications for certain patients.